AAC (NYSE:AAC) and Biocorrx (OTCMKTS:BICX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Risk & Volatility
AAC has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Biocorrx has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for AAC and Biocorrx, as reported by MarketBeat.com.
AAC currently has a consensus price target of $8.00, indicating a potential upside of 279.15%. Given AAC’s higher probable upside, research analysts plainly believe AAC is more favorable than Biocorrx.
Valuation and Earnings
This table compares AAC and Biocorrx’s revenue, earnings per share (EPS) and valuation.
AAC has higher revenue and earnings than Biocorrx.
This table compares AAC and Biocorrx’s net margins, return on equity and return on assets.
Insider & Institutional Ownership
66.2% of AAC shares are held by institutional investors. Comparatively, 0.0% of Biocorrx shares are held by institutional investors. 31.2% of AAC shares are held by company insiders. Comparatively, 21.4% of Biocorrx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
AAC beats Biocorrx on 10 of the 11 factors compared between the two stocks.
AAC Company Profile
AAC Holdings, Inc. provides inpatient and outpatient substance use treatment services for individuals with drug addiction, alcohol addiction, and co-occurring mental/behavioral health issues in the United States. Its therapy services include motivational interviewing, cognitive behavioral therapy, rational emotive behavior therapy, dialectical behavioral therapy, solution-focused therapy, eye movement desensitization and reprocessing, and systematic family intervention. As of June 30, 2018, the company operated 11 inpatient substance abuse treatment facilities, focused on delivering clinical care and treatment solutions across 1,112 inpatient beds, including 732 licensed detoxification beds, 26 standalone outpatient centers, and 5 sober living facilities across 409 beds for a total of 1,521 combined inpatient and sober living beds. It also offers Internet marketing services to families and individuals struggling with addiction and seeking treatment options through online directories of treatment providers, treatment provider reviews, forums, and professional communities; and online marketing solutions to other treatment providers, such as facility profiles, audience targeting, lead generation, and tools for digital reputation management. In addition, the company performs drug testing and diagnostic laboratory services; and provides physician services to its clients. AAC Holdings, Inc. was founded in 2014 and is headquartered in Brentwood, Tennessee.
Biocorrx Company Profile
BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. The company distributes and licenses BioCorRx recovery program, a medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant. It is also developing BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is headquartered in Anaheim, California.